D1.1: At least four target dyads designed on the paper (together with the respective monomers).

SUCCESSFULLY COMPLETED.

D1.2: At least one monomer synthesized in ca. 30 mg quantity and at least one of the dyads synthesized in ca. 10 mg quantity.

SUCCESSFULLY COMPLETED.

D2.1: Three target dyads designed on the paper.

SUCCESSFULLY COMPLETED.

D2.2: At least one target dyad synthesized in ca. 20 mg quantity.

SUCCESSFULLY COMPLETED.

D3.1: At least one dyad will perform sufficiently well to be delivered for microscopy validation.

SUCCESSFULLY COMPLETED.

D4.1: A log-log plot of fluorescence intensity versus excitation intensity (slope = 4 for a quartic dependence).

SUCCESSFULLY COMPLETED.

D4.2: Determination of the optimal Performance (0-1) for each of the validated compounds.

SUCCESSFULLY COMPLETED.

D5.1: At least one dyad that has been equipped with a solubilizing group.

ONGOING

D5.2: At least one dyad that passes all characterization/validation criteria.

D6.1: At least one dyad conjugated to a secondary antibody or peptide.

D6.2: A log-log plot to see if the quartic dependence is achievable in the cells and recommendations as for optimal Performance values in the cells.

D7.1: Signed Consortium Agreement.

COMPLETED.

D7.2: Opening and maintaining the website and social media channels.

ONGOING.

D7.3: Organization of presential meetings.

ONGOING.

D7.4: First press release.

ONGOING.

D7.5: Data Management Plan.

ONGOING.

D7.6: A first version of the Dissemination and Exploitation Plan.

ONGOING.

D7.7: End User Panel established.

COMPLETED.

D7.8: Midterm and final report.

D7.9: Final press release.